Skip to main content
. 2010 Jan 25;28(7):1099–1105. doi: 10.1200/JCO.2009.25.0597

Fig 2.

Fig 2.

Primary end point is progression-free survival. Kaplan-Meier estimator for PROSTVAC (a vaccine containing two recombinant viral vectors [vaccinia and fowlpox] and three immune costimulatory molecules [B7.1, ICAM-1, and LFA3]) arm is shown as a solid gold line and the estimator for the control arm is a dashed blue line. The small vertical tic marks show the censoring times. The estimated median progression-free survival is 3.8 months in the PROSTVAC arm and 3.7 months in the control arm.